The mortality risk in HIV-exposed, uninfected (HEU) children was about double that of HIV-unexposed, uninfected (HUU) children, according to a meta-analysis of studies reporting mortality of HEU children to age 60 months and associated factors. The authors said further research is needed to characterize the impact of maternal death and breastfeeding on the survival of HEU infants in the context of maternal antiretroviral therapy, where current evidence is limited.
A study published in Nature showed the efficacy of a single injection of four anti–HIV-1 neutralizing monoclonal antibodies (VRC01, VRC01-LS, 3BNC117, and 10-1074) in blocking repeated weekly low-dose virus challenges of the clade B simian/human chimeric virus AD8.
A systematic review of recent medical literature found that persons of low socioeconomic status in South Africa had a more than 50% higher risk of dying from HIV/AIDS. The authors reported increased relative risk for low-income people when analyzing for income, assets score, and employment status, although relative risk for education was not significant.
A study in HIV Clinical Trials concluded that the use of fosamprenavir/ritonavir therapy (FPV/r) is tolerated in HIV-infected patients with viral hepatitis coinfection. The investigators found the FPV/r discontinuation rate due to adverse events or alanine aminotransferase elevation was similar across all European-approved FPV/r doses and to that of patients on lopinavir/ritonavir therapy.
On Twitter @richpizzi